PL377333A1 - Preparaty depot o kontrolowanym uwalnianiu - Google Patents

Preparaty depot o kontrolowanym uwalnianiu

Info

Publication number
PL377333A1
PL377333A1 PL377333A PL37733303A PL377333A1 PL 377333 A1 PL377333 A1 PL 377333A1 PL 377333 A PL377333 A PL 377333A PL 37733303 A PL37733303 A PL 37733303A PL 377333 A1 PL377333 A1 PL 377333A1
Authority
PL
Poland
Prior art keywords
controlled release
depot formulations
release depot
formulations
controlled
Prior art date
Application number
PL377333A
Other languages
English (en)
Inventor
Guohua Chen
Paul Houston
Roy Bannister
Teresa Kameda
David Priebe
Lothar Kleiner
Original Assignee
Alza Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32312806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL377333(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corporation filed Critical Alza Corporation
Publication of PL377333A1 publication Critical patent/PL377333A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL377333A 2002-11-06 2003-11-04 Preparaty depot o kontrolowanym uwalnianiu PL377333A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42442802P 2002-11-06 2002-11-06

Publications (1)

Publication Number Publication Date
PL377333A1 true PL377333A1 (pl) 2006-01-23

Family

ID=32312806

Family Applications (1)

Application Number Title Priority Date Filing Date
PL377333A PL377333A1 (pl) 2002-11-06 2003-11-04 Preparaty depot o kontrolowanym uwalnianiu

Country Status (25)

Country Link
US (1) US7368126B2 (pl)
EP (1) EP1581181B1 (pl)
JP (1) JP2006508127A (pl)
KR (1) KR20050088288A (pl)
CN (1) CN1713890A (pl)
AR (1) AR041913A1 (pl)
AT (1) ATE418323T1 (pl)
AU (1) AU2003295409B2 (pl)
BR (1) BR0315304A (pl)
CA (1) CA2504608C (pl)
CL (1) CL2003002277A1 (pl)
DE (1) DE60325511D1 (pl)
EC (2) ECSP055838A (pl)
MA (1) MA27523A1 (pl)
MX (1) MXPA05004927A (pl)
MY (1) MY140155A (pl)
NO (1) NO20052635L (pl)
NZ (1) NZ539810A (pl)
PE (1) PE20040675A1 (pl)
PL (1) PL377333A1 (pl)
RU (1) RU2355385C2 (pl)
TW (1) TW200503774A (pl)
UY (1) UY28067A1 (pl)
WO (1) WO2004043432A2 (pl)
ZA (1) ZA200504529B (pl)

Families Citing this family (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060280774A1 (en) * 1995-06-02 2006-12-14 Allergan, Inc. Compositions and methods for treating glaucoma
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
ES2491866T3 (es) * 1999-11-15 2014-09-08 Piramal Healthcare (Canada) Limited Disolución biopolimérica acuosa autogelificante controlada por la temperatura y dependiente del pH
US20030158302A1 (en) * 1999-12-09 2003-08-21 Cyric Chaput Mineral-polymer hybrid composition
EP1255576B1 (en) * 1999-12-09 2003-08-20 Biosyntech Canada Inc. Mineral-polymer hybrid composition
US20050042194A1 (en) * 2000-05-11 2005-02-24 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
DK1294414T3 (da) * 2000-06-29 2006-07-24 Biosyntech Canada Inc Præparat og fremgangsmåde til heling og regenerering af brusk og andre væv
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
US20040091540A1 (en) * 2000-11-15 2004-05-13 Desrosiers Eric Andre Method for restoring a damaged or degenerated intervertebral disc
WO2002043785A2 (en) 2000-11-29 2002-06-06 Oculex Pharmaceuticals, Inc. Intraocular implants for preventing transplant rejection in the eye
US7829109B2 (en) * 2001-11-14 2010-11-09 Durect Corporation Catheter injectable depot compositions and uses thereof
US20070196415A1 (en) * 2002-11-14 2007-08-23 Guohua Chen Depot compositions with multiple drug release rate controls and uses thereof
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
JP2006503004A (ja) * 2002-07-31 2006-01-26 アルザ・コーポレーション 射出可能なデポ組成物及びその使用
DK1539101T3 (da) 2002-07-31 2009-04-27 Alza Corp Injicerbare, multi-modale polymere depotsammens tninger og anvendelser deraf
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
EP1610765B1 (en) * 2003-03-31 2008-08-13 ALZA Corporation Non-aqueous single phase vehicles and formulations utilizing such vehicles
CL2004000696A1 (es) * 2003-03-31 2005-05-20 Alza Corp Bomba osmotica, esta formada por una cubierta cilindrica con una camara que recibe al agente osmotico, un extremo abierto que recibe un tapon semipermeable y un orificio de ventilacion en la pared lateral ubicado proximo al extremo abierto, para disi
JP2006521898A (ja) * 2003-03-31 2006-09-28 アルザ・コーポレーション 浸透送り出しシステム及び浸透送り出しシステムの始動時間を短縮する方法
US20070184084A1 (en) * 2003-05-30 2007-08-09 Guohua Chen Implantable elastomeric caprolactone depot compositions and uses thereof
WO2004108111A1 (en) * 2003-05-30 2004-12-16 Alza Corporation Implantable elastomeric depot compositions, uses thereof and method of manufacturing
US20050106214A1 (en) * 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US8529927B2 (en) * 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
BRPI0510485A (pt) 2004-04-30 2007-11-13 Allergan Inc implantes inibidores de tirosina cinase intravìtreos biodegradáveis
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8425929B2 (en) 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US20050266087A1 (en) * 2004-05-25 2005-12-01 Gunjan Junnarkar Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
US8541028B2 (en) 2004-08-04 2013-09-24 Evonik Corporation Methods for manufacturing delivery devices and devices thereof
CN101060831B (zh) * 2004-10-01 2010-06-23 拉姆斯科股份有限公司 可方便植入的缓释药物组合物
US9993558B2 (en) 2004-10-01 2018-06-12 Ramscor, Inc. Sustained release eye drop formulations
US8541413B2 (en) * 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
TWI369218B (en) * 2004-12-14 2012-08-01 Novartis Ag In situ forming implant for animals
JP2008524235A (ja) * 2004-12-15 2008-07-10 キューエルティー ユーエスエー，インコーポレイテッド． オクトレオチド化合物の徐放性送達処方物
US20060141040A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
WO2006123360A2 (en) * 2005-03-01 2006-11-23 Sun Pharmaceutical Industries Limited Microspheres containing octreotide acetate
US7691816B2 (en) * 2005-07-12 2010-04-06 Renovo Ltd. Pharmaceutical compositions
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
EP1948810A4 (en) * 2005-11-04 2010-06-30 Biosyntech Canada Inc COMPOSITION AND METHOD USING CHITOSAN FOR THE EFFICIENT ADMINISTRATION OF NUCLEIC ACIDS TO CELLS
KR20080073328A (ko) * 2005-11-16 2008-08-08 토카이 유니버시티 에듀케이셔널시스템 약제 방출 제어 조성물 및 약제 방출성 의료 기구
WO2007071395A1 (en) * 2005-12-22 2007-06-28 Novartis Ag Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers
US8236904B2 (en) 2005-12-28 2012-08-07 Ethicon, Inc. Bioabsorbable polymer compositions exhibiting enhanced crystallization and hydrolysis rates
US20070149640A1 (en) * 2005-12-28 2007-06-28 Sasa Andjelic Bioabsorbable polymer compositions exhibiting enhanced crystallization and hydrolysis rates
US20070178138A1 (en) * 2006-02-01 2007-08-02 Allergan, Inc. Biodegradable non-opthalmic implants and related methods
DE602007009377D1 (de) 2006-05-30 2010-11-04 Intarcia Therapeutics Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
US20070298073A1 (en) * 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8802128B2 (en) * 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
EP2359808B1 (en) 2006-08-09 2013-05-22 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8846073B2 (en) 2006-12-19 2014-09-30 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
CN104000779A (zh) 2007-04-23 2014-08-27 精达制药公司 促胰岛素释放肽的混悬制剂及其应用
CN103007288B (zh) 2007-05-18 2015-02-11 杜雷科特公司 改进的贮库制剂
EP2907524A1 (en) 2007-05-25 2015-08-19 RB Pharmaceuticals Limited Sustained delivery formulations of risperidone compounds
WO2008149364A2 (en) * 2007-06-07 2008-12-11 Sarah Brenner Methods for diagnosing hypersensitivity reactions
US7923021B2 (en) * 2007-07-24 2011-04-12 University Of Memphis Research Foundation Local delivery method and composition
RU2343908C1 (ru) * 2007-09-05 2009-01-20 Руслан Дмитриевич Илюк Средство для профилактики и лечения алкоголизма и способ его применения
US8470360B2 (en) * 2008-04-18 2013-06-25 Warsaw Orthopedic, Inc. Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
US9090737B2 (en) * 2007-11-13 2015-07-28 Surmodics, Inc. Viscous terpolymers as drug delivery platform
ES2718612T3 (es) 2007-12-20 2019-07-03 Evonik Corp Procedimiento para preparar micropartículas que tienen un bajo volumen de disolvente residual
WO2009095450A1 (en) 2008-01-30 2009-08-06 Novartis Ag Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
AU2013201877B2 (en) * 2008-01-30 2015-01-29 Novartis Ag Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US8883768B2 (en) * 2008-04-18 2014-11-11 Warsaw Orthopedic, Inc. Fluocinolone implants to protect against undesirable bone and cartilage destruction
US7993666B2 (en) * 2008-04-18 2011-08-09 Warsaw Orthopedic, Inc. Methods and compositions for treating pain comprising a statin
US8956641B2 (en) * 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of inflammatory diseases
US9072727B2 (en) * 2008-04-18 2015-07-07 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of degenerative disc disease
US8524267B2 (en) * 2008-04-18 2013-09-03 Warsaw Orthopedic, Inc. Dexamethasone formulations in a biodegradable material
US20090263456A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Methods and Compositions for Reducing Preventing and Treating Adhesives
US8889173B2 (en) * 2008-04-18 2014-11-18 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
US8846068B2 (en) * 2008-04-18 2014-09-30 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising a local anesthetic
US8846770B2 (en) * 2008-06-18 2014-09-30 Otonomy, Inc. Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
SI2341905T2 (sl) * 2008-09-04 2024-02-29 Amylin Pharmaceuticals, Llc Formulacije s podaljšanim sproščanjem z uporabo brezvodnih nosilcev
US9623222B2 (en) * 2008-10-30 2017-04-18 Warsaw Orthopedic, Inc. Drug depot with anchor
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US20100151033A1 (en) * 2008-12-15 2010-06-17 Novartis Ag Octreotide depot formulation with constantly high exposure levels
US20100168807A1 (en) * 2008-12-23 2010-07-01 Burton Kevin W Bioactive terpolymer compositions and methods of making and using same
US9415197B2 (en) 2008-12-23 2016-08-16 Surmodics, Inc. Implantable suction cup composites and implants comprising same
US8951546B2 (en) 2008-12-23 2015-02-10 Surmodics Pharmaceuticals, Inc. Flexible implantable composites and implants comprising same
US20100158978A1 (en) * 2008-12-23 2010-06-24 Peter Markland Bioactive spray coating compositions and methods of making and uses thereof
US8974808B2 (en) * 2008-12-23 2015-03-10 Surmodics, Inc. Elastic implantable composites and implants comprising same
US20100228097A1 (en) * 2009-03-04 2010-09-09 Warsaw Orthopedic, Inc. Methods and compositions to diagnose pain
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
WO2011031996A2 (en) 2009-09-10 2011-03-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Engineered microparticles for macromolecule delivery
NO2462246T3 (pl) 2009-09-28 2018-02-03
US20110097380A1 (en) * 2009-10-28 2011-04-28 Warsaw Orthopedic, Inc. Clonidine formulations having antimicrobial properties
AU2010314990B2 (en) 2009-11-09 2015-10-01 Allergan, Inc. Compositions and methods for stimulating hair growth
US9993441B2 (en) 2009-12-30 2018-06-12 Surmodics, Inc. Controlled release matrix barrier structure for subcutaneous medical devices
CN107184544A (zh) * 2010-01-22 2017-09-22 阿勒根公司 前房内持续释放治疗药植入物
WO2011133370A1 (en) * 2010-04-23 2011-10-27 Medtronic, Inc. Shelf stable pharmaceutical depot
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513267B (en) * 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
WO2012030823A1 (en) * 2010-08-30 2012-03-08 Surmodics Pharmaceuticals, Inc. Biodegradable terpolymers and terpolymer blends as pressure-sensitive adhesives
CA2810842C (en) * 2010-09-09 2018-06-26 Micell Technologies, Inc. Macrolide dosage forms
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9597412B2 (en) 2011-03-16 2017-03-21 University Of Delaware Injectable delivery system for heparan-binding growth factors
CN102133180B (zh) * 2011-03-18 2016-03-09 黄芳 一种甾体5α-还原酶抑制剂长效注射制剂及其制备方法
US9005634B2 (en) 2011-04-13 2015-04-14 Medtronic, Inc. Shelf stable pharmaceutical depot
CN104127385B (zh) * 2011-04-25 2017-08-04 山东绿叶制药有限公司 利培酮缓释微球组合物
US8951996B2 (en) * 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
JP5952912B2 (ja) 2011-12-15 2016-07-13 アルカーメス ファーマ アイルランド リミテッド 二級アミン化合物のプロドラッグ
US9642697B2 (en) 2012-04-24 2017-05-09 Snu R&Db Foundation Breast prosthesis allowing controlled release of drug and production method for same
US8822423B2 (en) * 2012-05-17 2014-09-02 Janssen Biotech, Inc. Affinity peptides toward infliximab
KR20150058510A (ko) 2012-09-27 2015-05-28 알레간 인코포레이티드 단백질의 지속된 방출을 위한 생물분해성 약물 전달 시스템
US20140234389A1 (en) 2013-02-15 2014-08-21 Allergan, Inc. Sustained drug delivery implant
CN105163719B (zh) 2013-03-11 2019-03-08 度瑞公司 包含高粘度液体载体的可注射控制释放组合物
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
MX352907B (es) 2013-03-15 2017-12-13 Heron Therapeutics Inc Composiciones de un poliortoéster y un solvente aprótico.
ES2805880T3 (es) 2013-10-31 2021-02-15 Allergan Inc Implantes intraoculares que contienen prostamida y métodos de uso de éstos
CA2931547A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
BR112016012063B1 (pt) * 2013-12-31 2021-02-23 Pb&B Sa composição e usos da mesma
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CA2965895C (en) 2014-11-07 2019-08-06 Indivior Uk Limited The use of sustained-release buprenorphine formulations for the treatment of pain or opioid use disorders
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
EP3324890A4 (en) * 2015-07-23 2019-06-19 Allergan, Inc. GLACO-TREATMENT VIA INTRAKAMERAL EYE IMPLANTS
TWI754643B (zh) 2016-05-16 2022-02-11 美商因塔希亞治療公司 升糖素受體選擇性多肽和彼之使用方法
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
BR112018077259A2 (pt) 2016-06-30 2019-06-18 Durect Corporation formulações depot
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
BR112019026225A2 (pt) 2017-06-13 2020-06-30 The University Of British Columbia composições de pasta polimérica para liberação de fármacos
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
CN119185557A (zh) 2018-04-06 2024-12-27 阿玛治疗公司 用于控释治疗剂的组合物
CN109898236B (zh) * 2019-03-15 2021-12-14 深圳市光远生物材料有限责任公司 一种载药纳米纤维膜及其制备方法和应用
CA3167217A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
CN111548482B (zh) * 2020-04-02 2022-09-13 复旦大学 一氧化氮供体修饰的共聚物、包含其的缓释制剂及其制备方法与应用
CN116940358A (zh) 2021-01-12 2023-10-24 度勒科特公司 持续释放药物递送系统和有关的方法
CA3218153A1 (en) * 2021-06-30 2023-01-05 Soumya Rahima BENHABBOUR Injectable, biodegradable and removable polymer based drug suspension for ultra-long-acting drug delivery
CN116270491A (zh) * 2023-03-30 2023-06-23 北京博恩特药业有限公司 一种醋酸亮丙瑞林缓释微球及其制备方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797492A (en) * 1972-12-27 1974-03-19 Alza Corp Device for dispensing product with directional guidance member
US3887790A (en) * 1974-10-07 1975-06-03 Vernon H Ferguson Wrap-around electric resistance heater
US3987790A (en) 1975-10-01 1976-10-26 Alza Corporation Osmotically driven fluid dispenser
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
JPS5933320B2 (ja) * 1981-04-03 1984-08-15 株式会社東芝 光学的情報記録媒体
US4443340A (en) * 1981-10-09 1984-04-17 Betz Laboratories, Inc. Control of iron induced fouling in water systems
US4985404A (en) * 1984-10-04 1991-01-15 Monsanto Company Prolonged release of biologically active polypeptides
US4865845A (en) * 1986-03-21 1989-09-12 Alza Corporation Release rate adjustment of osmotic or diffusional delivery devices
US4853218A (en) * 1987-02-24 1989-08-01 Schering Corporation Zinc-protamine-alpha interferon complex
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5085866A (en) * 1988-12-02 1992-02-04 Southern Research Institute Method of producing zero-order controlled-released devices
US5059423A (en) * 1988-12-13 1991-10-22 Alza Corporation Delivery system comprising biocompatible beneficial agent formulation
US5057318A (en) * 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5112614A (en) * 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
US5234692A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5234693A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5151093A (en) * 1990-10-29 1992-09-29 Alza Corporation Osmotically driven syringe with programmable agent delivery
US5620700A (en) * 1990-10-30 1997-04-15 Alza Corporation Injectable drug delivery system and method
GB9027422D0 (en) * 1990-12-18 1991-02-06 Scras Osmotically driven infusion device
US5137727A (en) * 1991-06-12 1992-08-11 Alza Corporation Delivery device providing beneficial agent stability
US5288214A (en) * 1991-09-30 1994-02-22 Toshio Fukuda Micropump
FI933471L (fi) * 1991-12-19 1993-08-05 Mitsui Toatsu Chemicals Polyhydroxikarboxylsyra och foerfarande foer dess framstaellning
US5456679A (en) * 1992-02-18 1995-10-10 Alza Corporation Delivery devices with pulsatile effect
US5209746A (en) * 1992-02-18 1993-05-11 Alza Corporation Osmotically driven delivery devices with pulsatile effect
US5308348A (en) * 1992-02-18 1994-05-03 Alza Corporation Delivery devices with pulsatile effect
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US5242910A (en) * 1992-10-13 1993-09-07 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
EP1013270A3 (en) * 1992-12-02 2001-03-28 Alkermes Controlled Therapeutics, Inc. Controlled release growth hormone containing microspheres
US5468253A (en) * 1993-01-21 1995-11-21 Ethicon, Inc. Elastomeric medical device
EP0729353B2 (en) 1993-11-19 2012-09-12 Alkermes, Inc. Preparation of biodegradable microparticles containing a biologically active agent
US5556905A (en) * 1994-03-30 1996-09-17 Reilly Industries, Inc. Physically-modified degradable thermoplastic compositions
DK1125577T3 (da) * 1994-04-08 2006-06-19 Qlt Usa Inc Væskeformige medikamentindföringspræparater
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
UA10911C2 (uk) * 1994-08-10 1996-12-25 Мале Впроваджувальне Підприємство "Іhтерфалл" Біосумісhий гідрогель
US5639851A (en) * 1995-10-02 1997-06-17 Ethicon, Inc. High strength, melt processable, lactide-rich, poly(lactide-CO-P-dioxanone) copolymers
US6113624A (en) * 1995-10-02 2000-09-05 Ethicon, Inc. Absorbable elastomeric polymer
PT949905E (pt) * 1996-12-20 2001-12-28 Alza Corp Composicao de gel injectavel de efeito retardado e processo para a sua preparacao
US6193991B1 (en) * 1997-10-29 2001-02-27 Atul J. Shukla Biodegradable delivery systems of biologically active substances
MXPA01012471A (es) 1999-06-04 2002-07-30 Alza Corp Composiciones de gel implantables y metodo de fabricacion..
CN1283215C (zh) 2000-06-28 2006-11-08 A·J·舒克拉 生物活性物质的可生物降解载体和释放系统
WO2002038185A2 (en) * 2000-11-13 2002-05-16 Atrix Laboratories, Inc. Injectable sustained release delivery system with loperamide
WO2002058670A1 (en) 2001-01-25 2002-08-01 Euroceltique S.A. Local anesthetic, and method of use
US7824700B2 (en) 2001-02-23 2010-11-02 Genentech, Inc. Erodible polymers for injection
BR0206984A (pt) * 2001-11-14 2004-02-03 Alza Corp Composições de depósito injetáveis e uso destas
US7829109B2 (en) * 2001-11-14 2010-11-09 Durect Corporation Catheter injectable depot compositions and uses thereof
CN100446809C (zh) * 2001-11-14 2008-12-31 阿尔扎有限公司 可注射的长效组合物
US20040001889A1 (en) * 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
AR039729A1 (es) 2002-06-25 2005-03-09 Alza Corp Formulaciones de deposito de corta duracion
JP2006503004A (ja) * 2002-07-31 2006-01-26 アルザ・コーポレーション 射出可能なデポ組成物及びその使用
DK1539101T3 (da) * 2002-07-31 2009-04-27 Alza Corp Injicerbare, multi-modale polymere depotsammens tninger og anvendelser deraf
US20050106214A1 (en) * 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
US20050281879A1 (en) * 2003-11-14 2005-12-22 Guohua Chen Excipients in drug delivery vehicles

Also Published As

Publication number Publication date
EP1581181B1 (en) 2008-12-24
RU2355385C2 (ru) 2009-05-20
AU2003295409B2 (en) 2010-02-11
EP1581181A2 (en) 2005-10-05
ATE418323T1 (de) 2009-01-15
CA2504608C (en) 2013-01-08
BR0315304A (pt) 2005-08-16
WO2004043432A2 (en) 2004-05-27
ECSP056249A (es) 2006-10-17
HK1085387A1 (en) 2006-08-25
NZ539810A (en) 2008-03-28
JP2006508127A (ja) 2006-03-09
TW200503774A (en) 2005-02-01
US7368126B2 (en) 2008-05-06
UY28067A1 (es) 2003-12-31
MY140155A (en) 2009-11-30
NO20052635D0 (no) 2005-06-01
ECSP055838A (es) 2005-09-20
RU2005117164A (ru) 2006-01-20
NO20052635L (no) 2005-07-20
PE20040675A1 (es) 2004-09-25
CN1713890A (zh) 2005-12-28
CL2003002277A1 (es) 2005-05-06
MA27523A1 (fr) 2005-09-01
AR041913A1 (es) 2005-06-01
US20040151753A1 (en) 2004-08-05
WO2004043432A3 (en) 2004-07-08
CA2504608A1 (en) 2004-05-27
ZA200504529B (en) 2006-08-30
MXPA05004927A (es) 2005-09-08
AU2003295409A1 (en) 2004-06-03
KR20050088288A (ko) 2005-09-05
DE60325511D1 (de) 2009-02-05

Similar Documents

Publication Publication Date Title
PL377333A1 (pl) Preparaty depot o kontrolowanym uwalnianiu
TWI347202B (en) Controlled release preparation
LT2279729T (lt) Kontroliuojamo atpalaidavimo preparatas
GB0218157D0 (en) Compositions for controlled release
IL162642A0 (en) Formulations
IL166424A0 (en) Sustained release formulations comprising lamotigine
GB0323701D0 (en) Formulations
GB0203421D0 (en) Composition
PL376840A1 (pl) Kompozycja farmaceutyczna o przedłużonym uwalnianiu
ZA200500677B (en) Short duration depot formulations
GB0203280D0 (en) Anti-glycolytic composition
GB0218194D0 (en) Solid formulations
GB0307765D0 (en) Tissue-adhesive formulations
TWI346555B (en) Vaccine composition
EP1495751A4 (en) hair dye
GB0214147D0 (en) Formulations
GB0211444D0 (en) Controlled release formulations
GB0215656D0 (en) Controlled release composition
GB0311354D0 (en) Controlled release formulations
GB0111389D0 (en) Controlled release formulations
GB0218567D0 (en) Formulations
GB0218037D0 (en) Vaccine composition
GB0203616D0 (en) Composition
TWI346556B (en) Vaccine composition
GB0322044D0 (en) Controlled release compositions

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)